P255 Effects of EDG-5506, a fast myosin modulator, on function and biomarkers of muscle damage in adults with Becker muscular dystrophy (BMD)Sarah Collins, J. Donovan, H. Phan et al.|Neuromuscular Disorders|2023Cited by 1
P254 Characterization of short- and long-term proteomic response to the fast skeletal myosin inhibitor, EDG-5506, in Becker muscular dystrophy (BMD)B. Barthel, Alan J. Russell, Mary Madden et al.|Neuromuscular Disorders|2023Cited by 0
349P Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD)B. Barthel, Alan J. Russell, Mary Madden et al.|Neuromuscular Disorders|2024Cited by 0
614PCANYON trial results: sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in BMDC. McDonald, J. Donovan, H. Kushlaf et al.|Neuromuscular Disorders|2025Cited by 0